208 related articles for article (PubMed ID: 34807331)
21. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
[TBL] [Abstract][Full Text] [Related]
22. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
[TBL] [Abstract][Full Text] [Related]
23. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
[TBL] [Abstract][Full Text] [Related]
24. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
[TBL] [Abstract][Full Text] [Related]
25. Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
Fukui T; Sasaki J; Igawa S; Kada A; Saito TI; Kogure Y; Okamoto H; Naoki K
BMC Cancer; 2022 Dec; 22(1):1314. PubMed ID: 36522630
[TBL] [Abstract][Full Text] [Related]
26. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
[TBL] [Abstract][Full Text] [Related]
27. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M; Terrasa J; Garrido P; Campelo RG; Aparisi F; Diz P; Aguiar D; García-Giron C; Hidalgo J; Aguado C; González JG; Esteban E; Gómez-Aldavarí L; Moran T; Juan O; Chara LE; Marti JL; Castro RL; Ortega AL; Moreno EM; Coves J; Sánchez Peña AM; Bosch-Barrera J; Gastaldo AS; Núñez NF; Del Barco E; Cobo M; Isla D; Majem M; Navarro F; Calvo V
BMC Cancer; 2021 Mar; 21(1):230. PubMed ID: 33676426
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
[TBL] [Abstract][Full Text] [Related]
30. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.
Ono T; Igawa S; Ozawa T; Kasajima M; Ishihara M; Hiyoshi Y; Kusuhara S; Nishinarita N; Fukui T; Kubota M; Sasaki J; Hisashi M; Katagiri M; Naoki K
Thorac Cancer; 2019 Apr; 10(4):880-889. PubMed ID: 30821083
[TBL] [Abstract][Full Text] [Related]
32. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
Popat S; Jung HA; Lee SY; Hochmair MJ; Lee SH; Escriu C; Lee MK; Migliorino MR; Lee YC; Girard N; Daoud H; Märten A; Miura S
Lung Cancer; 2021 Dec; 162():9-15. PubMed ID: 34649106
[TBL] [Abstract][Full Text] [Related]
33. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA; Han JY; Dafni U; Cho BC; Yeo CM; Nadal E; Carcereny E; de Castro J; Sala MA; Bernabé R; Coate L; Provencio Pulla M; Garcia Campelo R; Cuffe S; Hashemi SMS; Früh M; Massuti B; Garcia-Sanchez J; Dómine M; Majem M; Sanchez-Torres JM; Britschgi C; Pless M; Dimopoulou G; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA; Peters S;
Ann Oncol; 2022 Feb; 33(2):181-192. PubMed ID: 34839016
[TBL] [Abstract][Full Text] [Related]
34. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
[TBL] [Abstract][Full Text] [Related]
35. Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer.
Isobe K; Yoshizawa T; Sekiya M; Miyoshi S; Nakamura Y; Urabe N; Isshiki T; Sakamoto S; Takai Y; Tomida T; Adachi-Akahane S; Iyoda A; Homma S; Kishi K
Respir Investig; 2021 Jul; 59(4):535-544. PubMed ID: 33934994
[TBL] [Abstract][Full Text] [Related]
36. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
Hizal M; Bilgin B; Paksoy N; Açıkgöz Ö; Sezer A; Gürbüz M; Ak N; Yücel Ş; Ayhan M; Erol C; Demirkıran A; Mandel NM; Shbair A; Gökmen İ; Başoğlu T; Paydaş S; Demiray AG; İriağaç Y; Şakalar T; Zeynelgil E; Tatlı AM; Bahçeci A; Güven DC; Caner B; Can A; Gülmez A; Karakaş Y; Yalçın B; Demirkazık A; Bilici A; Aydıner A; Yumuk PF; Şendur MAN
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1501-1508. PubMed ID: 34331582
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.
Knetki-Wróblewska M; Kowalski DM; Czyżewicz G; Bryl M; Wrona A; Dziadziuszko R; Kieszko R; Milanowski J; Świniuch D; Ramlau R; Krzakowski M
Adv Respir Med; 2020; 88(3):189-196. PubMed ID: 32706102
[TBL] [Abstract][Full Text] [Related]
38. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
39. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Ramalingam SS; Yang JC; Lee CK; Kurata T; Kim DW; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett JC; Thress KS; Jänne PA
J Clin Oncol; 2018 Mar; 36(9):841-849. PubMed ID: 28841389
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
Li X; Zhang D; Li B; Zou B; Wang S; Fan B; Li W; Yu J; Wang L
Lung Cancer; 2021 Jan; 151():39-43. PubMed ID: 33296806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
